Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Feb 11:13:86.
doi: 10.3389/fnins.2019.00086. eCollection 2019.

Oxidative Stress Related to Iron Metabolism in Relapsing Remitting Multiple Sclerosis Patients With Low Disability

Affiliations

Oxidative Stress Related to Iron Metabolism in Relapsing Remitting Multiple Sclerosis Patients With Low Disability

Mariacristina Siotto et al. Front Neurosci. .

Abstract

Oxidative status may play a role in chronic inflammation and neurodegeneration which are considered critical etiopathogenetic factors in Multiple Sclerosis (MS), both in the early phase of the disease and in the progressive one. The aim of this study is to explore oxidative status related to iron metabolism in peripheral blood of stable Relapsing-Remitting MS with low disability. We studied 60 Relapsing-Remitting MS patients (age 37.2 ± 9.06, EDSS median 1.0), and 40 healthy controls (age 40.3 ± 10.86). We measured total hydroperoxides (dROMs test) and Total Antioxidant Status (TAS), along with the iron metabolism biomarkers: Iron (Fe), ferritin (Ferr), transferrin (Tf), transferrin saturation (Tfsat), and ceruloplasmin (Cp) panel biomarkers [concentration (iCp) and enzymatic activity (eCp), copper (Cu), ceruloplasmin specific activity (eCp:iCp), copper to ceruloplasmin ratio (Cu:Cp), non-ceruloplasmin copper (nCp-Cu)]. We computed also the Cp:Tf ratio as an index of oxidative stress related to iron metabolism. We found lower TAS levels in MS patients than in healthy controls (CTRL) and normal reference level and higher dROMs and Cp:Tf ratio in MS than in healthy controls. Cp and Cu were higher in MS while biomarkers of iron metabolism were not different between patients and controls. Both in controls and MS, dROMs correlated with iCp (CTRL r = 0.821, p < 0.001; MS r = 0.775 p < 0.001) and eCp (CTRL r = 0.734, p < 0.001; MS r = 0.820 p < 0.001). Moreover, only in MS group iCp correlated negatively with Tfsat (r = -0.257, p = 0.047). Dividing MS patients in "untreated" group and "treated" group, we found a significant difference in Fe values [F(2, 97) = 10.136, p < 0.001]; in particular "MS untreated" showed higher mean values (mean = 114.5, SD = 39.37 μg/dL) than CTRL (mean 78.6, SD = 27.55 μg/dL p = 0.001) and "MS treated" (mean = 72.4, SD = 38.08 μg/dL; p < 0.001). Moreover, "MS untreated" showed significantly higher values of Cp:Tf (mean = 10.19, SD = 1.7710-2; p = 0.015), than CTRL (mean = 9.03, SD = 1.46 10-2). These results suggest that chronic oxidative stress is relevant also in the remitting phase of the disease in patients with low disability and short disease duration. Therefore, treatment with antioxidants may be beneficial also in the early stage of the disease to preserve neuronal reserve.

Keywords: ceruloplasmin; ceruloplasmin:transferrin ratio; hydroperoxides; iron metabolism; multiple sclerosis; oxidative stress; total antioxidant status.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Scattered dot plot with bar plot (mean with SD) of total antioxidant status (TAS), hydroperoxides (dROMs), ceruloplasmin transferrin ratio (Cp:Tf), and ceruloplasmin (iCp) in CTRL and MS.
FIGURE 2
FIGURE 2
(A,B) Correlation between hydroperoxides (dROMs) and ceruloplasmin (iCp and eCp, respectively) in CTRL. (C,D) Correlation between hydroperoxides (dROMs) and ceruloplasmin (iCp and eCp, respectively) in MS. (E) Correlation between ceruloplasmin (iCp) vs. transferrin saturation (TfSat %) in MS. A p-value < 0.05 was considered statistically significant.
FIGURE 3
FIGURE 3
Bar plot (mean with SD) of iron (Fe) and ceruloplasmin transferrin ratio (Cp:Tf) in CTRL, MS in disease modifying therapy (treated MS), and in MS not in disease modifying therapy (untreated MS).

Similar articles

Cited by

References

    1. Abe A., Yamashita S., Noma A. (1989). Sensitive, direct colorimetric assay for copper in serum. Clin. Chem. 35 552–554. - PubMed
    1. Adamczyk B., Adamczyk-Sowa M. (2016). New insights into the role of oxidative stress mechanisms in the pathophysiology and treatment of multiple sclerosis. Oxid. Med. Cell. Longev. 2016:1973834. 10.1155/2016/1973834 - DOI - PMC - PubMed
    1. Alberti A., Bolognini L., Macciantelli D., Caratelli M. (2000). The radical cation of N,N-Diethyl-para-phenylendiamine: a possible indicator of oxidative stress in biological samples. Res. Chem. Intermed. 26 253–267. 10.1163/156856700X00769 - DOI
    1. Alimonti A., Ristori G., Giubilei F., Stazi M. A., Pino A., Visconti A., et al. (2007). Serum chemical elements and oxidative status in Alzheimer’s disease, Parkinson disease and multiple sclerosis. Neurotoxicology 28 450–456. 10.1016/j.neuro.2006.12.001 - DOI - PubMed
    1. Altamura C., Squitti R., Pasqualetti P., Gaudino C., Palazzo P., Tibuzzi F., et al. (2009). Ceruloplasmin/Transferrin system is related to clinical status in acute stroke. Stroke 40 1282–1288. 10.1161/STROKEAHA.108.536714 - DOI - PubMed